About US
Contact us
-
The $38B pie: Pfizer, Moderna COVID-19 vaccines set for lion's share of 2021 salesWith the first COVID-19 vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies leading the vaccine race, with major blockbuster revenues on the li2020/12/4
-
Merck cashes in on Moderna COVID-19 vaccine enthusiasm with sale of equity stakeWhen Merck invested $100 million in cash and stock in Moderna back in 2015, and then another $125 million three years later, the term “mRNA” was barely known outside of biotech circles. But now2020/12/3
-
Lonza plots 2 manufacturing suites for antibody-drug conjugates at Switzerland siteThe search for next-gen oncology therapies has sparked an arms race in biopharma to find the next big thing—whether that's in cell and gene therapies or promising antibody-drug conjugates (ADCs). Eye2020/12/3
-
CDMO Sterling plots buyout of antibody-drug conjugate specialist in play at next-gen oncology marketA little more than two months after bolstering its manufacturing presence in the U.S., CDMO Sterling Pharma Solutions is expanding its scope once more, this time in the realm of next-gen cancer meds.2020/12/2
-
Who's your pick for the next FDA chief? Nominate now, start voting next weekBefore President-elect Joe Biden announces his own choice for the FDA top spot, Fierce Pharma wants to know what readers think. Who do you think is the best man or woman to serve as the nation’s next2020/12/2
-
Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing studyEven as the FDA has already approved or authorized several COVID-19 drugs, the search for better therapies is still underway—and despite some high-profile failures, repurposing existing drugs remains2020/12/1
-
Pharma AstraZeneca hands European Crestor rights to old customer Grünenthal for $350MAstraZeneca has reached for the ax again, with old cholesterol blockbuster Crestor its latest target. The British pharma hasagreed to sellCrestor rights in more than 30 European countries to Grünenth2020/12/1
-
Why isn't Pfizer's COVID-19 vaccine OK'd yet? White House calls in FDA chief Hahn to explain: AxiosThroughout the pandemic, White House officials have twisted arms at the FDA—and sometimes succeeded.Now, in the final months ofthe Trump administration, agency chief Stephen Hahn, M.D., has been summ2020/11/30
-
AstraZeneca staffers targeted in suspected hacking scheme amid work on COVID-19 vaccine: reportAfter China, Iran and Russia, North Korea is the latest to be fingered for attempting to steal Western research intoCOVID-19. Its target? AstraZeneca. North Korean hackersusedsham recruiting schemes2020/11/27
-
McKinsey consultants proposed Purdue offer rebates for opioid overdoses: NYTPurdue Pharma has faced years ofintensescrutiny over its opioid painkiller marketing, culminating withlast month’sDepartment of Justice settlement worth more than $8 billion.Behind the scenes,global2020/11/27